Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | PKM | P14618 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.37 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | ATR | Q13535 | 1/20 | 0.36 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.36 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29585697 | 1.00 | NPSR1 (0.48) | NPSR1KDM4EL3MBTL1ALDH1A1PKM | |
| SCHEMBL20046668 | 0.87 | NPSR1 (0.56) | NPSR1KDM4EL3MBTL1ALDH1A1PKM | |
| SCHEMBL4979826 | 0.86 | ALDH1A1 (0.33) | NPSR1KDM4EL3MBTL1ALDH1A1MAPK1 | |
| SCHEMBL3581736 | 0.85 | NPSR1 (0.48) | NPSR1KDM4EL3MBTL1ALDH1A1PKM | |
| SCHEMBL18779093 | 0.84 | NPSR1 (0.47) | NPSR1KDM4EL3MBTL1ALDH1A1PKM | |
| SCHEMBL361753 | 0.84 | NPSR1 (0.47) | NPSR1KDM4EL3MBTL1ALDH1A1PKM | |
| SCHEMBL29844624 | 0.84 | NPSR1 (0.47) | NPSR1KDM4EL3MBTL1ALDH1A1PKM | |
| SCHEMBL31279531 | 0.84 | NPSR1 (0.47) | NPSR1KDM4EL3MBTL1ALDH1A1PKM | |
| SCHEMBL23981557 | 0.82 | NPSR1 (0.45) | NPSR1KDM4EL3MBTL1ALDH1A1PKM | |
| SCHEMBL17325904 | 0.82 | NPSR1 (0.45) | NPSR1KDM4EL3MBTL1ALDH1A1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 194 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12606541-B2 | PPARg modulators and methods of use | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2026-04-21 | — | — | US | disclosed |
| US-20260022114-A1 | N-(5-SUBSTITUTED-[(1,3,4-THIADIAZOLYL) OR (1,3-THIAZOLYL)](SUBSTITUTED)CARBOXAMIDE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING THE AMIDE COMPOUNDS AND OF THEIR USE | GILEAD SCIENCES, INC. | 2026-01-22 | — | — | US | disclosed |
| US-12441736-B2 | KIF18A inhibitors | AMGEN INC. (US) | 2025-10-14 | — | — | US | disclosed |
| US-12435058-B2 | KIF18A inhibitors | AMGEN INC. (US) | 2025-10-07 | — | — | US | disclosed |
| EP-4007753-B1 | KIF18A INHIBITORS | AMGEN INC (US) | 2025-09-24 | — | — | EP | disclosed |
| EP-4594316-A1 | N-(5-SUBSTITUTED-[(1,3,4-THIADIAZOLYL) OR (1,3-THIAZOLYL)](SUBSTITUTED)CARBOXAMIDE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING THE AMIDE COMPOUNDS AND OF THEIR USE | Repare Therapeutics Inc. (CA) | 2025-08-06 | — | — | EP | disclosed |
| US-20250195511-A1 | INDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF NOD-LIKE RECEPTOR PROTEIN 3 | MERCK SHARP & DOHME LLC (US) | 2025-06-19 | — | — | US | disclosed |
| WO-2025128777-A1 | INDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF NOD-LIKE RECEPTOR PROTEIN 3 | MERCK SHARP & DOHME LLC (US) | 2025-06-19 | — | — | WO | disclosed |
| US-12331056-B2 | SHP2 phosphatase inhibitors and methods of use thereof | RELAY THERAPEUTICS, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| US-20250188040-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | VIVIDION THERAPEUTICS INC | 2025-06-12 | — | — | US | disclosed |
| US-7220736-B2 | Pyrimidine compounds | TANABE SEIYAKU CO., LTD. (JP) | 2007-05-22 | — | — | US | disclosed |
| EP-1219609-B1 | AROMATIC NITROGENOUS SIX-MEMBERED RING COMPOUNDS | TANABE SEIYAKU CO (JP) | 2007-04-04 | — | — | EP | disclosed |
| US-6797709-B2 | SEXUAL DISORDERS | TANABE SEIYAKU CO., LTD. (JP) | 2004-09-28 | — | — | US | disclosed |
| US-20040142930-A1 | Cyclic compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2004-07-22 | — | — | US | disclosed |
| US-20030229089-A1 | Cyclic compounds | TANABE SEIYAKU CO., LTD. (JP) | 2003-12-11 | — | — | US | disclosed |
| US-20030229095-A1 | Sexual disorders | TANABE SEIYAKU CO., LTD. | 2003-12-11 | — | — | US | disclosed |
| US-6656935-B2 | Treatment of penile erectile dysfunction, pulmonary hypertension, and diabetic gastroparesis | TANABE SEIYAKU CO., LTD. (JP) | 2003-12-02 | — | — | US | disclosed |
| US-20030032647-A1 | Treatment of penile erectile dysfunction, pulmonary hypertension, and diabetic gastroparesis | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2003-02-13 | — | — | US | disclosed |
| EP-1277741-A1 | CYCLIC COMPOUNDS | TANABE SEIYAKU CO., LTD. (JP) | 2003-01-22 | — | — | EP | disclosed |
| EP-1219609-A1 | AROMATIC NITROGENOUS SIX-MEMBERED RING COMPOUNDS | TANABE SEIYAKU CO., LTD. (JP) | 2002-07-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030032647-A1 | Treatment of penile erectile dysfunction, pulmonary hypertension, and diabetic gastroparesis | PDE3A, PDE3B, PDE2A | NPSR1 169/4885KDM4E 651/4885L3MBTL1 4403/4885 |
| US-20260022114-A1 | N-(5-SUBSTITUTED-[(1,3,4-THIADIAZOLYL) OR (1,3-THIAZOLYL)](SUBSTITUTED)CARBOXAMIDE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING THE AMIDE COMPOUNDS AND OF THEIR USE | POLK, POLQ, POLB | NPSR1 4413/4885KDM4E 1824/4885L3MBTL1 3276/4885 |
| US-12441736-B2 | KIF18A inhibitors | KIF18A, KIF18B, KIF15 | NPSR1 4311/4885KDM4E 1251/4885L3MBTL1 3184/4885 |
| US-20030229095-A1 | Sexual disorders | PDE3B, PDE3A, PDE2A | NPSR1 80/4885KDM4E 210/4885L3MBTL1 4774/4885 |
| US-20250195511-A1 | INDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF NOD-LIKE RECEPTOR PROTEIN 3 | NLRP3, FABP3, NOD1 | NPSR1 57/4885KDM4E 4848/4885L3MBTL1 1751/4885 |
| US-20030229089-A1 | Cyclic compounds | PDE3B, PDE5A, PDE9A | NPSR1 559/4885KDM4E 999/4885L3MBTL1 4708/4885 |
| US-12606541-B2 | PPARg modulators and methods of use | PPARG, PPARA, PPARD | NPSR1 1419/4885KDM4E 2304/4885L3MBTL1 4535/4885 |
| US-12435058-B2 | KIF18A inhibitors | KIF18A, KIF18B, KIF15 | NPSR1 4335/4885KDM4E 1372/4885L3MBTL1 3496/4885 |
| US-20040142930-A1 | Cyclic compounds | PDE3B, PDE4A, PDE5A | NPSR1 571/4885KDM4E 732/4885L3MBTL1 4703/4885 |
| US-20250188040-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | RECQL, BLM, WRN | NPSR1 4482/4885KDM4E 3220/4885L3MBTL1 1538/4885 |
| US-12331056-B2 | SHP2 phosphatase inhibitors and methods of use thereof | PTPRCAP, PTPN22, PTPN1 | NPSR1 3152/4885KDM4E 756/4885L3MBTL1 3077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.